Contemporary outcomes after endovascular treatment for aorto-iliac artery disease
| Autor: | Yoshimitsu Soga, Osamu Iida, Daizo Kawasaki, Yasutaka Yamauchi, Kenji Suzuki, Keisuke Hirano, Ryoji Koshida, Daisuke Kamoi, Junichi Tazaki, Michiaki Higashitani, Yoshiaki Shintani, Terutoshi Yamaoka, Shinya Okazaki, Nobuhiro Suematsu, Taketsugu Tsuchiya, Yusuke Miyashita, Norihiko Shinozaki, Hiroki Takahashi, null on behalf of REAL-AI investigators |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Aortic Diseases Iliac Artery Disease-Free Survival Blood Vessel Prosthesis Implantation Sex Factors Internal medicine parasitic diseases medicine Vascular Patency Humans Myocardial infarction Registries Stroke Survival rate Cause of death Aged Retrospective Studies Aspirin business.industry Endovascular Procedures Retrospective cohort study General Medicine Middle Aged medicine.disease Surgery Survival Rate Cardiology Female Stents Cardiology and Cardiovascular Medicine business Mace medicine.drug |
| Zdroj: | Circulation journal : official journal of the Japanese Circulation Society. 76(11) |
| ISSN: | 1347-4820 |
| Popis: | Background: The patency and complications in aorto-iliac (AI) stenting remain poorly understood. The aim of this paper was to investigate the safety and efficacy after AI stenting. Methods and Results: This study was performed as a large-scale multicenter, retrospective registry. A total of 2,147 consecutive patients with AI disease were enrolled. The safety endpoints were procedure success, complications and 30-day mortality. The efficacy endpoints were primary, assisted primary and secondary patency, overall survival, freedom from major adverse cardiovascular events (MACE; all-cause death, myocardial infarction and stroke), and major adverse cardiovascular and limb events (MACLE; any repeat revascularization for limb and leg amputation in addition to MACE). Procedure success, complication rate and 30-day mortality were 97.6%, 6.4% and 0.7%. Primary patency was 92.5%, 82.6% and 77.5% at 1, 3 and 5 years, assisted primary patency was 97.0%, 92.7% and 91.9% at 1, 3 and 5 years and secondary patency was 99.0%, 98.7% and 98.5% at 1, 3 and 5 years. The overall survival rate was 95.0%, 87.6%, and 79.3% at 1, 3 and 5 years. The cause of death was cardiovascular in 44.1%. Freedom from MACE (MACLE) was 93.3% (89.9%), 84.4% (76.7%), and 74.9% (66.8%) at 1, 3 and 5 years. Female gender, diabetes, renal failure, absence of aspirin, reference vessel diameter |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|